Nexentis Technologies Inc. Common Stock (NXTS) is a publicly traded the market company. As of May 21, 2026, NXTS trades at $4.43 with a market cap of $3.61M and a P/E ratio of 0.00. NXTS moved +0.00% today. Year to date, NXTS is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $3.38 to $8.33. Rallies surfaces NXTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nexentis Subsidiary MitoCareX Unveils Optimized Hit Molecule with Improved Drug Properties: MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, generated an optimized hit molecule with substantially improved pharmaceutical properties using the MITOLINE® algorithm platform. The small-molecule candidate targets a mitochondrial SLC25 carrier protein for hard-to-treat cancers and inflammatory metabolic diseases and now advances toward preclinical lead optimization.
| Metric | Value |
|---|---|
| Price | $4.43 |
| Market Cap | $3.61M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.33 |
| 52-Week Low | $3.38 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
NXTS analyst coverage data. Average price target: $0.00.